Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN2060 in Japanese Participants With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
NCT04622046Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Alexion Pharmaceuticals. Primary endpoints: 6-Minute Walk Distance at 12 months, Cardiovascular-Related Hospitalizations at 30 months and 1 more. Started Nov 2020; status: completed.
02
Drugs
acoramidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT04622046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622046.